
Assessing CD38 Monoclonal Antibody-Based Regimens in NDMM
In a recent Around the Practice program, CancerNetwork® hosted a panel discussion focused on CD38 monoclonal antibody treatment in patients with newly diagnosed multiple myeloma (NDMM). Initially, the panel discussed whether the emergence of daratumumab ( …